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There is sparse evidence on community practice patterns in treating women with breast cancer. This study compared care of women
with breast cancer with evidence from meta-analyses and US National Comprehensive Cancer Network (NCCN) clinical guidelines.
Records of 4395 women with breast cancer were abstracted from practices of 19 surgeon oncologists in six specialty practices in the
Philadelphia region during 1995–1999. Patients were followed through December 2001. Low-frequency data were obtained on all
patients. All other data were from a random sample of 464 women, minimum of 50 patients per practice. Actual care provided was
compared to NCCN guidelines and results of meta-analyses. Fewer than half the women received treatments reflecting meta-analysis
results or NCCN guidelines, by disease stage/TNM status. Adherence to either standard varied from 0% for LCIS to 87% for stages
IIA or IIB node positive. There are multiple interactive reasons for low adherence to guidelines or meta-analyses results, including
insufficient health system supports to clinicians, inadequate organisation and delivery systems and ineffective continuing medical
education. The paucity of written information from patient records on physician/patient interactions limits the understanding of
treatment decisions.
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Breast cancer outcomes have improved over time because of more
effective treatments, greater public awareness and earlier diagnosis
(Smart et al, 1997). Factors contributing to outcomes variability
include unequal access to care (Mandelblatt et al, 1999), age (Bailar
and Gornik, 1997), ethnicity and income (Roetzheim et al, 2000),
patient treatment preferences (Ashcroft et al, 1985; Contant et al,
2000; Mandelblatt et al, 2000), surgeon preferences (Mor et al,
2000) and geography (Farrow et al, 1996; Coleman et al, 1999;
Polednak, 2000; Morrow et al, 2001). The objective of this study
was to compare actual care with published guidelines and best
evidence from meta-analyses.
METHODS AND MATERIALS
Study site and patient accrual
Six single-specialty surgical oncology practices in northeastern US
with 19 oncology surgeons participated. Patients entered the study
after diagnosis of breast cancer and operation between 1 January
1995 and 31 December 1999, and were followed through 31
December 2001. None were in clinical trials.
We used two sampling methods to collect data. From the total
patient population (n¼4395) we collected specific low-frequency
data determined by study pretest. Next, we selected a random
sample (n¼464) from each practice based on volume of breast
cancer patients, with a minimum of 50 patients from each practice.
Utilisation of five treatments were selected because each were
included in clinical practice guidelines and confirmed by meta-
analyses:
1. breast-conserving surgery (BCS) and mastectomy;
2. breast reconstruction following operation;
3. adjuvant cytotoxic chemotherapy;
4. radiation;
5. nonsteroidal antioestrogens.
Treatment algorithms
We chose four treatment algorithms from two sources. Treatment
recommendations by both were the same or similar by diagnosis
and stage. The first comparator was the US National Comprehen-
sive Cancer Network (NCCN) clinical practice guidelines (NCNN,
1996). The second was derived from treatment-specific meta-
analyses of optimal care for each clinical scenario by diagnosis/
TNM/stage. We used only meta-analyses published before 1996 as
1995 was the beginning of patient enrollment.
Breast-conserving surgery or mastectomy
NCCN guideline: For DCIS, LCIS and stages I and node-negative
IIa, BCS with negative margins, BCS plus radiation, or mastectomy
without lymph node dissection, are equally appropriate, unless the
woman chooses otherwise.
Meta-analyses: Bradley et al (1990)found similar mortality for
women treated with mastectomy or BCS for early stage DCIS and
LCIS despite higher recurrence rates with BCS.
Received 4 August 2003; revised 2 October 2003; accepted 2 October
2003
*Correspondence: BS Bloom, Division of Geriatrics, Department of
Medicine, University of Pennsylvania, Philadelphia, PA 19104-2676, USA;
E-mail: bsbloom@mail.med.upenn.edu
British Journal of Cancer (2004) 90, 26–30
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lBreast reconstruction
NCCN guideline: All women should have the option of breast
reconstruction following mastectomy.
Meta-analyses: There were no meta-analyses and limited results
from controlled research (Harcourt and Rumsey, 2001). NCCN
recommends BCS, and patient preference (Ashcroft et al, 1985;
Mandelblatt et al, 2000), satisfaction (Contant et al, 2000),
psychological impact (Noon et al, 1982; Schain et al, 1984; Stevens
et al, 1984) and self-image (Sneeuw et al, 1992; Al-Ghazal et al,
2000) show its importance to women.
Radiation therapy
NCCN guideline: All women with DCIS and negative margins,
and all women with BCS or mastectomy with T3 and greater should
have radiation of standard fractionated doses totaling 40–60Gy,
unless contraindicated and/or the woman refuses.
Meta-analyses: The Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG) found reduced relapse rates and comparable
mortality for radiation following operation regardless of stage and
node status EBCTCG, 1995). Radiation and BCS for DCIS reduces
recurrence by 50% (Bradley et al, 1990; Boyages et al, 1999).
Cytotoxic chemotherapy
NCCN guideline: Multicycle adjuvant cytotoxic polychemother-
apy should be prescribed for all women with node positive disease
and/or with tumour greater than 1cm, except for DCIS and LCIS,
unless the woman refuses.
Meta-analyses: Himel et al (1986) found significant survival
benefits with cytotoxic polychemotherapy. EBCTCG (1988, 1992)
concluded that it reduced annual risk of death by 16% and disease
recurrence by 28%, irrespective of stage and node status .
Nonsteroidal antioestrogens
NCCN guideline: Women with positive oestrogen receptor (OR)
and/or progesterone receptor (PR) disease, irrespective of
diagnosis and disease stage, should receive a nonsteroidal
antioestrogen unless contraindicated and/or the woman refuses.
Meta-analyses: EBCTCG (1988, 1992)found that tamoxifen re-
duced mortality and disease recurrence for women with OR/PR-
positive disease. Combining chemotherapy with tamoxifen re-
duced 10-year relative mortality risk by 30–40%.
Other interventions Axillary node dissection was included in
treatment algorithms because NCCN recommended it in their
guidelines even though no meta-analysis was published until 1999
(Orr, 1999). Modified radical mastectomy or lumpectomy plus
axillary node dissection were also included.
Combined treatment algorithms Four scenarios were developed
from NCCN guidelines and meta-analyses. Each algorithm from
both sources was compared to actual patient treatment. It is to be
noted that a treatment prescribed by the physician that followed
either algorithm was considered appropriate even if the women
refused or did not complete therapy.
RESULTS
Patient characteristics
There were 4395 women in the entire study and 464 women (10.
6%) in the study random sample. Patient age was uniformly
distributed from p45 to 480 years (Table 1). Ethnicity mirrored
the region’s population except for under representation of
Hispanics. Every woman in the study had health insurance, and
51.9% had known ambulatory pharmaceutical coverage.
Physician characteristics
All 19 study physicians were board certified general surgeons and
specialized in breast cancer care. In all, two-thirds were male and
17 were Caucasian; all practices were partnerships.
Nearly all patients had numerous consultations with multiple
physicians and others in addition to their surgeon, for example,
radiation oncologists, psychiatrists and nutritionists. About 85%
continued regular visits to the surgeon from study entry to study
completion or death.
Disease characteristics
Diagnostic testing Use of diagnostic tests recommended by
NCCN varied – OR/PR status (81.6% of women), HER/2 neu
oncogene (2.2%), Ki67 (27.6%) and BCRA1/BCRA2 (0.2%). Except
for use of OR/PR status, none were included in treatment
algorithms.
Based on TNM status, most women (82.4%) had early stage
disease (0, I or IIa) (Table 2), similar to US national data (Lazovich
et al, 1991).
Utilisation of five individual treatments
Breast-conserving surgery Breast-conserving surgery was pro-
vided to 47.1% of women in the study sample (n¼464) (Table 3),
higher than results from a national US study (42.6%) (Morrow et al,
2001). Fewer than 1% refused lumpectomy and chose mastectomy.
The majority (69.5%) of women with node-positive disease had
modified radical mastectomy regardless of disease stage. Among
the 85 women with disease recurrence (n¼4395), 32.9% had
lumpectomy and the remainder mastectomy.
Breast reconstruction Breast reconstruction was provided to
20.8% of women within 1 year after mastectomy (Table 3), nearly
two-fold higher than reports of the same period (Polednak, 2000;
Morrow et al, 2001). In addition, 1.5% of women with lumpectomy
had breast reconstruction.
Radiation therapy Radiation was provided to 56.8% of women
(Table 3). Over 90% received recommended fractionated doses
totaling 40–60Gy (28); 98% completed their regimen. Fewer than
1% refused radiation.
Table 1 Patient age and ethnicity at breast cancer diagnosis
Age Total % White % Non-White % Unknown
o45 13.6 58.7 19.1 22.2
45–49 11.0 60.8 15.7 23.5
50–54 10.8 58.0 14.0 28.0
55–59 10.1 76.6 14.9 8.5
60–64 8.2 60.5 10.5 29.0
65–69 11.6 57.4 20.4 22.2
70–74 9.7 75.6 8.9 15.6
75–79 9.3 65.1 20.9 14.0
80–84 5.2 79.2 8.3 12.5
85–89 1.7 62.5 0 37.5
90+ 0.6 100.0 0 0
Unknown 8.2 63.2 15.8 21.0
Total % 100.0 64.7 15.0 20.3
Mean: 60.25 s.d. 13.77
Skewness: 0.077
Min: 24 Max: 94
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given to 37.1% of eligible women (Table 3). A total of 19 (4.1%)
had neoadjuvant plus adjuvant regimens. Two refused all
chemotherapy.
Nonsteroidal antioestrogens Of women with OR- and/or PR-
positive disease, 80.4% received a nonsteroidal antioestrogen,
nearly always tamoxifen, including the 8% who refused (Table 3).
Most who refused did so because of potential side effects. Nearly
5% were diagnosed with recurrent breast cancer while on
tamoxifen for secondary prophylaxis.
Among women with recorded previous history of deep venous
thrombosis (DVT) or pulmonary embolus (PE) (n¼95 of the total
population of 4395), 60.0% (n¼57) got tamoxifen, of whom 83.3%
(n¼47) experienced another DVT or PE. All were OR or PR
positive; none died. None were on recorded anticoagulation
therapy.
Physician adherence with optimal or NCCN guideline treatments
Optimal or NCCN treatments were provided to 45.0% of women
(Table 4). The majority at every disease stage, except those with
DCIS, was not treated according to NCCN practice guidelines or
optimal regimens from meta-analyses. Overuse of mastectomy,
and under use of lumpectomy, reconstruction, radiation and
cytotoxic polychemotherapy were the main results for every
disease stage and scenario.
Factors associated with service use
We tested by logistic regression all independent patient, physician,
disease and treatment variables to determine which influenced
treatment variations. Patient age was inversely related with breast
reconstruction (P¼0.006), cytotoxic polychemotherapy
(Po0.001) and radiation (P¼0.02). Patient age (Po0.0001) was
directly, and surgeon female gender (P¼0.007) inversely, related
to tamoxifen use.
Odds ratios (ORs) analyses found that patient age was inversely
related to radiation (OR¼0.98, CI .963–.997) and cytotoxic
polychemotherapy (OR¼0.91, CI 0.891–0.938), and directly
related to tamoxifen use (OR¼1.04, CI 1.02–1.05). Surgeon
female gender was inversely related to tamoxifen (OR¼0.51,
CI¼0.312–0.837). No differences from either analysis were
clinically significant.
Cluster analysis of individual treatments by physician, using
fixed-effects and random-effects models, found no significant
associations with independent variables. Thus, no variables had
important systematic effect on treatment variation from NCCN
guidelines and meta-analyses.
DISCUSSION
Most women with breast cancer in this study were not treated
according to regimens from either meta-analyses or NCCN clinical
practice guidelines. In only one scenario (DCIS) was the majority
of women treated according to either standard. These findings are
consistent with a 1998 study of physician adherence with US
National Institutes of Health clinical practice guidelines for early
stage breast cancer, and with a 2002 study of all beneficial breast
cancer diagnostic and therapeutic interventions (Lazovich et al,
1991; Malin et al, 2002).
Table 2 Disease stage at diagnosis (N¼464)
Stage Percent
Stage 0,I 55.0
Stage IIa 27.4
Stage IIb 8.6
Stage IIIa 3.7
Stage IIIb 3.0
Stage IV 2.4
Total 100.1
Table 3 Percent of women prescribed individual optimal or NCCN
recommended treatments, by diagnosis and disease stage (N¼464)
Diagnosis and stage
Treatment
DCIS, stage I
or IIa node neg
(n¼354)
LCIS
(n¼14)
IIa or IIb
node pos
(n¼34)
IIIA, IIIB, IV
(n¼61)
Lumpectomy 64.2 33.3 17.4 14.3
Axillary node dissection N/A N/A 8.7 7.1
Sentinal node biopsy N/A N/A 8.7 2.4
Simple/modified radical
mastectomy
10.9 N/A 73.9 67.4
Reconstruction
a 4.2 33.3 13.0 19.0
Radiation 60.4 30.4 39.1 40.5
Chemotherapy 19.2 N/A 34.8 26.2
Tamoxifen, if OR and/or
PR positive
79.5 66.7 56.5 60.6
aFollowing any mastectomy. N/A¼not applicable.
Table 4 Prescribing optimal or NCCN clinical guideline treatment (N¼464)
Clinical scenario
(1) DCIS, and/or stage I, or IIA node negative (N¼354)
Meta analysis optimal treatment: lumpectomy, radiation and tamoxifen if OR and/or PR positive, unless the woman refuses 44.7%
NCCN practice guidelines: mastectomy with unclear disease margins, or BCS with negative margins plus radiation, plus breast reconstruction and
tamoxifen if OR positive, unless the woman refuses
59.6%
(2) LCIS (N¼14)
Meta analysis optimal treatment: lumpectomy, radiation and tamoxifen if OR and/or PR positive, unless the woman refuses 14.2%
NCCN practice guidelines: observation alone, or bilateral mastectomy plus reconstruction, unless the woman refuses 0%
(3) Stage IIa or IIb node positive (N¼34)
Meta analaysis optimal treatment and NCCN practice guidelines: BCS with/without axillary node dissection or sentinal node biopsy, or modified radical
mastectomy plus reconstruction, radiation, polychemotherapy, and tamoxifen if OR and/or PR positive, unless the woman refuses
14.7%
(4) Stage IIIa, IIIB, or IV (N¼61)
Meta analysis optimal treatment: BCS with/without axillary node dissection, or modified radical mastectomy plus breast reconstruction, and radiation,
polychemotherapy and tamoxifen if OR and/or PR positive, unless the woman refuses
42.2%
NCCN practice guidelines: modified radical mastectomy plus breast reconstruction, radiation, polychemotherapy, and tamoxifen if OR and/or PR
positive, unless the woman refuses
11.8%
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treatment. Physician-specific treatment at the beginning was
essentially the same as at the end of the study, suggesting that
incorporation of best evidence and clinical practice guidelines is
slow in altering clinical care patterns. However, available meta-
analyses published by 1995 may not have been available long
enough to influence change.
Over- and undertreatment occurred simultaneously, sometimes
in the same patient. For example, excluding women who requested
it, 15.1% with DCIS or stage I, with clear margins, had mastectomy,
an example of over treatment based on NCCN guidelines and
meta-analyses; and only 15.6% had breast reconstruction within a
year, an example of under treatment. In another example,
tamoxifen was provided to 60% of women with known history of
DVT or PE, a contraindication for use. Lack of specifics on detailed
discussions between patient and physician means we do not know
how and why decisions on specific care modalities were made.
What might account for discordance between actual and
recommended or optimal treatment? First, there are likely
important differences between patients in randomized control
trials and general patients treated in the community. Community
patients have variable disease and personal preferences, and
physicians tailor treatment to individual needs. An unanswered
question is whether physicians who participate in randomised
trials practice according to their own study results, and differently
than physicians not participating in trials.
Second, two recent reports by the US Institute of Medicine
(IOM) clearly noted health system organisation, delivery and
financing deficiencies, results likely applicable to many countries
(Institute of Medicine, 2001, 2002). There are inappropriate
incentives and inadequate supports and mechanisms to help
physicians and patients understand, choose and adhere to
treatments with the greatest likelihood of benefit. Tying patient
care processes to predefined outcomes may provide impetus for
change (Institute of Medicine, 2001). Any recommendations for
changes in physician practice must be coupled with increased
patient participation and adherence to prescribed care (Morrison
et al, 2000).
An equally knotty problem is physician continuing medical
education (CME) to incorporate best scientific evidence into
clinical practice. Commonly used CME methods like lectures and
distributing printed materials alone have little or no success in
changing physician clinical practice. Other techniques, like group
interactive learning and reminders and audit and feedback are
highly effective, but infrequently used (Grimshaw et al, 1994;
Thomson O’Brien et al, 2002).
Study limitations
The most serious study limitation was lack of written information
on patient and physician discussions and treatment choices. Next,
a patient cohort treated in one geographic region may not be
representative of all women with breast cancer and thus may
reduce external validity.
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